Rectal indomethacin to prevent post-ERCP pancreatitis

New England Journal of Medicine

Volumn 367, Issue 3, 2012, Pages 277-279

  Baron, Todd H ^a   Abu Dayye, Barham K ^a   Zinsmeister, Alan R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN;

DISEASE SEVERITY; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HIGH RISK PATIENT; HUMAN; LETTER; PANCREATIC STENT; PANCREATITIS; PHYSICAL PARAMETERS; PRIORITY JOURNAL; RISK REDUCTION; STENT; STENT DIAMETER; TREATMENT OUTCOME; VATER PAPILLA STENOSIS;

EID: 84864022430     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1205928     Document Type: Letter

References (5)

1. Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012;366:1414-22.
2. Tarnasky PR, Palesch YY, Cunningham JT, Mauldin PD, Cotton PB, Hawes RH. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998;115:1518-24. (Pubitemid 28546003)
3. Saad AM, Fogel EL, McHenry L, et al. Pancreatic duct stent placement prevents post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction but normal manometry results. Gastrointest Endosc 2008;67:255-61.
4. Chahal P, Tarnasky PR, Petersen BT, et al. Short 5Fr vs long 3Fr pancreatic stents in patients at risk for post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2009;7:834-9.
5. Zolotarevsky E, Fehmi SM, Anderson MA, et al. Prophylactic 5-Fr pancreatic duct stents are superior to 3-Fr stents: a randomized controlled trial. Endoscopy 2011;43:325-30.